AUTHOR=Sanetra Krzysztof , Buszman Piotr Paweł , Jankowska-Sanetra Justyna , Cisowski Marek , Fil Wojciech , Gorycki Bogdan , Bochenek Andrzej , Slabon-Turska Monika , Konopko Marta , Kaźmierczak Paweł , Gerber Witold , Milewski Krzysztof , Buszman Paweł Eugeniusz TITLE=One-stage hybrid coronary revascularization for the treatment of multivessel coronary artery disease— Periprocedural and long-term results from the “HYBRID-COR” feasibility study JOURNAL=Frontiers in Cardiovascular Medicine VOLUME=Volume 9 - 2022 YEAR=2022 URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1016255 DOI=10.3389/fcvm.2022.1016255 ISSN=2297-055X ABSTRACT=Background: The constant growth of interest in hybrid coronary artery revascularization (HCR) is apparent. Yet, few studies report outcomes of the one-stage HCR. Consequently, the status of such procedures is not adequately supported in clinical guidelines. The aim of this study was to report safety, feasibility and long term-outcomes of the one-stage HCR. Methods and Results:  Patients were enrolled into the prospective one-stage hybrid coronary revascularization program (HYBRID-COR). They underwent one-stage hybrid revascularization procedure whilst on double antiplatelet therapy (DAPT) with Ticagrelor: endoscopic atraumatic coronary artery bypass grafting (EACAB) for revascularization of left anterior descending (LAD) artery and percutaneous intervention in non-LAD arteries with contemporary drug eluting stents. The composite primary endpoint included MACCE (major adverse cardiac and cerebrovascular events: death, myocardial infarction, stroke, repeat revascularization) in a long-term observation. The study cohort consisted of 30 patients (68% male) with stable coronary artery disease (26.7%) and unstable angina (73.3%). Procedural success was 100%. No death, myocardial infarction (MI) or stroke were observed in the perioperative period. One patient (3.3%) required chest revision and blood transfusion due to surgical bleeding. Kidney injury was noted in 2 patients (6.6%). In a long term follow-up (median; IQR: 4.25; 2.62- 4.69 years), two patients (6.6%) underwent repeat revascularization and one patient (3.3%) died due to MI. Overall primary endpoint rate was 9.9%. Conclusions: One-stage hybrid revascularization, on DAPT, is a feasible, safe and efficient way of achieving complete revascularization in selected patients. The complication rate is low and acceptable. Further randomized trials are required.